A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Dana Farber/massachusetts General Hospital, Inc
Boston, Massachusetts, United States
Leon PappasRecruiting - Scri Lake Mary
Nashville, Tennessee, United States
Recruiting - Scri Oncology Partners
Nashville, Tennessee, United States
Recruiting - New Experimental Therapeutics of San Antonio Llc
San Antonio, Texas, United States
Dr. Anthony TolcherRecruiting - Start - South Texas Accelerated Research Therapeutics, Llc
San Antonio, Texas, United States
Dr. Drew RascoRecruiting - Start Mountain Region
West Valley City, Utah, United States
Dr. William McKeanRecruiting - Next Virginia
Fairfax, Virginia, United States
Alexander SpiraRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Dec 2024
- Primary completion
- 15 Dec 2026
- Completion
- 16 Jun 2027
- Last update posted
- 18 Dec 2025
- Registered enrollment
- 115
- Registry id
- NCT06797336
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.